Atrasentan mandelate salts
AssigneeAbbVie Inc.
InventorsYuchuan Gong, Geoff G. Zhang
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents; (d) methods for the preparation of an atrasentan mandelate salt; and (e) atrasentan mandelate salts prepared by such method.
Claims11
A crystalline atrasentan S-mandelate anhydrous salt wherein the molar ratio of atrasentan to S-mandelate is about 1:1.
Dependencies are inferred from the claim text.